[{"id":"70b20d35-1924-438c-943b-f1f8ed19928b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04007978","created_at":"2021-01-18T19:41:39.157Z","updated_at":"2024-07-02T16:36:57.223Z","phase":"Phase 1","brief_title":"Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies","source_id_and_acronym":"NCT04007978","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anti-CD22 CAR-T therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/05/2019","start_date":" 08/05/2019","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2019-08-07"}]